Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis
Iyas Daghlas, Vascular Neurology Fellow and Stroke Researcher at the University of California, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Excited to share our new publication in Neurology: ‘Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis: A Mendelian Randomization Study.’
Cerebral venous thrombosis (CVT) is a rare form of stroke treated with anticoagulation.
Despite widespread off-label direct oral anticoagulant (DOAC) use, no adequately powered RCT has demonstrated DOAC efficacy, and many patients continue to be treated with warfarin, which carries substantial major bleeding risk.
We addressed this evidence gap by examining effects of naturally randomized genetic variants perturbing the protein targets of established (F2+F10) and emerging (F11) DOACs.
See Table 1 for a cool demonstration of the natural allocation of covariates/confounders across genotypes, mimicking an RCT ‘Table 1.’
We found evidence that genetically reduced levels of thrombin, factor Xa, and factor XI are associated with reduced CVT risk – see forest plot!
What this means:
- FXI inhibitors (milvexian, asundexian, etc) are among the most actively investigated therapeutic targets in thrombosis today, with multiple Phase III trials underway. Our data provide the first human genetic evidence supporting repurposing potential for CVT, a new indication for this drug class.
- Human genetics supports efficacy for established DOAC protein targets (thrombin and factor Xa) in reducing CVT risk
- These data support the notion that, in general, therapeutics that are effective for venous thromboembolism will likely also work for CVT
Appreciate collaborators Marta Pérez Alcántara and Dipender Gill!”
Title: Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis. A Mendelian Randomization Study
Authors: Iyas Daghlas, Marta Pérez Alcántara, Dipender Gill
Read the Full Article on Neurology
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 30, 2026, 17:43Santagata Davide: Can Targeting Inflammation Help Prevent Thrombosis?
-
Oct 30, 2026, 17:38Patrick Ellsworth: Supporting Patients and Families Through Bleeding Disorders Awareness and Community Initiatives
-
Oct 30, 2026, 17:33Ed Shovelin: Comparative Hemostatic Performance of CRP-A and Equine Fibrillar Collagen
-
Oct 30, 2026, 16:52Tosin Ola: A New Era in Sickle Cell Disease Treatment and the Question of Access
-
Oct 30, 2026, 16:48Cedric Hermans: The Next Generation of FVIIIa-Mimetic Antibodies in Haemophilia A
-
Oct 30, 2026, 16:44Shehab Mohamed: Recognizing Isolated Thrombocytopenia as a Presentation of MDS
-
Oct 30, 2026, 16:40Amrita Sarkar: Advancing the Diagnosis of Anti-PF4 Syndromes
-
Oct 30, 2026, 16:35James Garrard: Driving Innovation in Stroke Care Through Global Collaboration
-
Oct 30, 2026, 16:19Cesar de Almeida Neto: Hemo 2026 Roundtable Focuses on the Challenges of Patient Blood Management